Wanner C - Search Results

1

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Zinman B, et al. Among authors: wanner c. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. N Engl J Med. 2015. PMID: 26378978 Free article. Clinical Trial.

2

Inflammation and cardiovascular risk in dialysis patients.

Wanner C, Zimmermann J, Schwedler S, Metzger T. Wanner C, et al. Kidney Int Suppl. 2002 May;(80):99-102. doi: 10.1046/j.1523-1755.61.s80.18.x. Kidney Int Suppl. 2002. PMID: 11982822 Free article.

3

C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients.

Wanner C, Metzger T. Wanner C, et al. Nephrol Dial Transplant. 2002;17 Suppl 8:29-32; discussion 39-40. doi: 10.1093/ndt/17.suppl_8.29. Nephrol Dial Transplant. 2002. PMID: 12147774 Review.

4

The metabolic burden of diabetes and dyslipidaemia in chronic kidney disease.

Krane V, Wanner C. Krane V, et al. Among authors: wanner c. Nephrol Dial Transplant. 2002;17 Suppl 11:23-7. doi: 10.1093/ndt/17.suppl_11.23. Nephrol Dial Transplant. 2002. PMID: 12386253 Review.

5

Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study.

Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Ketteler M, et al. Among authors: wanner c. Lancet. 2003 Mar 8;361(9360):827-33. doi: 10.1016/S0140-6736(03)12710-9. Lancet. 2003. PMID: 12642050

6

Diabetic nephropathy: an inherited disease or just a diabetic complication?

Berger M, Mönks D, Wanner C, Lindner TH. Berger M, et al. Among authors: wanner c. Kidney Blood Press Res. 2003;26(3):143-54. doi: 10.1159/000071880. Kidney Blood Press Res. 2003. PMID: 12886042 Free article. Review.

7

Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics.

Wanner C, Krane V, März W, Olschewski M, Asmus HG, Krämer W, Kühn KW, Kütemeyer H, Mann JF, Ruf G, Ritz E; Deutsche Diabetes-Dialyse-Studie (4D) Study Group. Wanner C, et al. Kidney Blood Press Res. 2004;27(4):259-66. doi: 10.1159/000080241. Epub 2004 Aug 16. Kidney Blood Press Res. 2004. PMID: 15316128 Free article. Clinical Trial.

8

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators. Wanner C, et al. N Engl J Med. 2005 Jul 21;353(3):238-48. doi: 10.1056/NEJMoa043545. N Engl J Med. 2005. PMID: 16034009 Free article. Clinical Trial.

9

Dyslipidemia, inflammation and dialysis outcomes: what we know now.

Krane V, Drechsler C, Wanner C. Krane V, et al. Among authors: wanner c. Curr Opin Nephrol Hypertens. 2006 Nov;15(6):566-70. doi: 10.1097/01.mnh.0000247501.41420.dd. Curr Opin Nephrol Hypertens. 2006. PMID: 17053468 Review.

10

Lipid metabolism in chronic kidney disease: the role of statins in cardiovascular risk.

Wanner C, Drechsler C, Krane V. Wanner C, et al. J Ren Nutr. 2007 Jan;17(1):75-8. doi: 10.1053/j.jrn.2006.10.012. J Ren Nutr. 2007. PMID: 17198938 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results